Koninklijke Philips Wins Dutch Court Shareholder Recall Battle

### Money Play Investors tracking broader health technology and litigation-linked sectors should monitor regulatory developments across international jurisdictions as multi-country investigations continue.

## Catalyst Analysis: Court Dismissal of Shareholder Probe The Enterprise Chamber of the Amsterdam Court of Appeal dismissed demands from shareholders, including the Dutch investors' association VEB, for an official inquiry into Koninklijke Philips NV's handling of the 2021 sleep apnea device recall. According to the court, management did not fail to act promptly on safety concerns or mislead investors, finding insufficient grounds to question internal policies or management practices. The court noted that reliable research data regarding the PE-PUR sound-abatement foam risks emerged in early 2021 and that executive and supervisory boards did not receive delayed warnings.

## Technical Analysis & Key Risk Watch

71.54 · R1 ## Technical Analysis & Key Risk Watch 70.72 · last ## Technical Analysis & Key Risk Watch 70.70 · S1 ## Technical Analysis & Key Risk Watch 70.59 · S2 ## Technical Analysis & Key Risk Watch 68.45.

While the Dutch court sided with management regarding governance and disclosures, the ruling explicitly does not determine liability or decide whether investors are entitled to compensation for losses tied to the recall, which caused shares to shed approximately two-thirds of their value. Ongoing legal and regulatory scrutiny remains a primary risk factor, underscored by the $1.1 billion settlement agreed upon in 2024 to resolve personal injury claims in the United States, alongside active investigations by prosecutors in countries such as France examining aggravated fraud allegations and failure to report safety risks.

## Impact on Sector and Ongoing Liabilities The resolution in the Amsterdam Court of Appeal removes an immediate corporate governance inquiry for Philips, yet health technology peers and institutional holders continue to navigate residual liability exposure from the 15 million devices recalled globally in 2021. Observers are closely following cross-border prosecutorial proceedings to gauge the total financial and reputational horizon for medical device manufacturers facing delayed safety disclosures.